New agents for Gram-positive bacteria

Infections caused by multiple-resistant Gram-positive organisms continue to occur at an alarming rate worldwide. Two new and unique antimicrobial agents targeted specifically against such organisms, quinupristin/dalfopristin and linezolid, have been approved for use in the USA in the past year and w...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Current Opinion in Microbiology 2000-10, Vol.3 (5), p.528-534
Hauptverfasser:	Bhavnani, Sujata M, Ballow, Charles H
Format:	Artikel
Sprache:	eng
Schlagworte:	Acetamides - therapeutic use AECB acute exacerbations of chronic bronchitis AMS acute maxillary sinusitis Anti-Bacterial Agents - therapeutic use CAP community-acquired pneumonia Clinical Trials as Topic dalfopristin Drug Approval Fluoroquinolones Glycopeptides Gram-Positive Bacterial Infections - drug therapy Humans Linezolid MIC minimum inhibitory concentration Oxazolidinones - therapeutic use Q/D quinupristin/dalfopristin quinupristin Streptococcus pneumoniae Virginiamycin - analogs & derivatives
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Infections caused by multiple-resistant Gram-positive organisms continue to occur at an alarming rate worldwide. Two new and unique antimicrobial agents targeted specifically against such organisms, quinupristin/dalfopristin and linezolid, have been approved for use in the USA in the past year and will play an important role in the treatment of life-threatening infections. In addition, several new fluoroquinolones have been approved recently or will be available in the near future to aid in the treatment of infections caused by resistant strains of Streptococcus pneumoniae.
ISSN:	1369-5274 1879-0364
DOI:	10.1016/S1369-5274(00)00134-X